Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab

NCT05877859 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT05877859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05877859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
Lead sponsor
Emory University
Phase
Observational
Overall status
Recruiting
Start date
May 30, 2023
Completion date
February 20, 2028
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer invasive, breast cancer stage ii, breast cancer stage iii, breast cancer triple negative